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Abstract 
 
This paper evaluates medicine prices, their availability and affordability in Brazil, 
considering the differences across three types of medicines on the market (originator 
brands, generics and similar medicines) and different types of facilities (private 
pharmacies, public sector pharmacies and “popular pharmacies”), using an established 
methodology. Data on prices and availability of 50 medicines (originator brand, lowest-
priced generic and similar medicines) were collected from public, private and popular 
pharmacies (N=56) across six cities in Southern Brazil. Median prices obtained are 
divided by international reference prices to derive the median price ratio (MPR). In the 
private sector, prices were 8.6 MPR for similar medicines, 11.3 MRP for generics and 
18.7 MRP for originator brands, respectively. Mean availability was 65%, 74% and 
48% for originator brands, generics and similars, respectively. The number of working 
days needed to pay for a complete medicine treatment (affordability) varied 
considerably between medicines aimed at treating acute and chronic diseases and by 
type of medicine. In the public sector, the mean availability of similar medicines was 2-
7 times higher than that of generics. The mean overall availability in the public sector 
ranged from 68.8% to 81.7%. In “popular pharmacies”, mean availability was greater 
than 90% in all cities. This analysis finds that availability of medicines in the public 
sector does not meet the challenge for supplying essential medicines to the entire 
population, as stated in the Brazilian constitution. This has unavoidable repercussions 
for affordability, particularly amongst the lower socio-economic strata. Policies targeted 
to reduce the prices of the generics need to be implemented in Brazil, as well as making 
them more widely available. Popular pharmacies may help overcome the lack of 
medicines in the public sector, but the limited number of medicines distributed in these 
facilities is of concern. 
 
Keywords: Drugs; Generics; Drug costs; Developing countries; National Health 
Programs; Pharmaceutical policy; Brazil  
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1. Background  
 
Although access to medicines in Brazil is relatively high 5, 31, major socioeconomic 
differences are observed 5. Despite poor families receiving more medicines free of 
charge from government-funded sources than the better-off, around 25.5% of the 
medicines obtained by the bottom income quintile of the population are paid for entirely 
out-of-pocket 5.   
 
Overall, Brazilian families spend 9.0% of their household income on health, and 
medicines account for the largest proportion of all health expenses 35; 31.5% of monthly 
health expenses and 2.0% of monthly family income were shown to be spent on 
medicines purchased out-of-pocket 3. A similar situation was previously reported in 
Estonia, among others39. Although the majority of the Brazilian population uses the 
Universal Health System (SUS) which should cover medicines from a select list, 25% 
of all families pay for private health insurance 36, which in Brazil does not cover the 
costs of medicines used in ambulatory care.  
 
Medicine access relates both to affordability and availability (available stock of 
essential medicines in pharmacies). Availability, particularly in the public sector, is an 
issue of considerable concern in Brazil.  Recent research, using data from across the 
country, found that for 71% of medicines the availability of generics was below 10% 28. 
International evidence, using data from 36 low and middle-income countries, showed 
that in the public sector, availability ranged from 29 to 54% and prices for private 
patients were 9 to 25 times higher than international reference prices for generics and 20 
times higher for originator products 17. 
 
Taking into account that both the availability of medicines, particularly in the public 
sector, and their price  in the private sector  are important determinants of access to 
medicines, this study aims to investigate medicine prices, availability and affordability 
in the Brazilian state of Rio Grande do Sul, located in the South of the country. 
Particular attention is given to the three types of medicines available in Brazil, notably 
originator brands, generics and similar medicines and the different types of facilities 
(private pharmacies, public sector pharmacies and pharmacies from the programme 
“Farmácia Popular do Brasil”, referred to as “popular pharmacy”). The paper adds to 
the current knowledge by exploring the effect of (a) type of facility and (b) type of 
medicine on availability, prices and affordability in Brazil.  
 
Section two discusses medicines coverage in the Brazilian context. Section three 
describes the methods used in data collection and analysis, whereas section four 
presents the main results of the analysis. Sections five and six discuss the findings and 
present conclusions and pharmaceutical policy implications, respectively.  
 
2. Coverage of medicines in the Brazilian context 
 
Health care in Brazil is largely publicly financed. Since 1988, Brazil has a universal 
health system (SUS), which is committed to providing health care to the population at 
no cost, including the distribution of a list of medicines considered to be essential 
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(National List of Essential Medicines) for all. In principle, availability of medicines 
from this list in the public sector should be 100%.  
In 2007, total national health expenditure reached were R$224.5 billion (US$ 96.5 
billion)i, which represents 8.4% of the gross domestic product (GDP). The per capita 
figure was R$1,159 (US$498.4). The users paid 57.4% of these expenses (4.8% of 
GDP), whereas 41.6% were paid for by the Brazilian government (3.5% of GDP). The 
remaining 0.1% was paid for by non-profit organizations. Out-of-pocket expenditure on 
medicines reached R$44.8 (US$19.3) billion in 2007. This figure represents 35% of all 
families’ health expenses for the same period. The government spent 1.9% of GDP on 
ambulatory medicine purchases. This figure does not include vaccines and medicines 
dispensed in hospitals. In 2007, families spent 10 times more money on medicines than 
the government 22.  
 
With the publication of the National Medicines Policy in 1998 16, several programs 
were launched aiming to guarantee medicine access to the population. Therefore, 
governmental expenses on medicines increased both in absolute terms and as a 
proportion of health expenditure. A recent study showed that government expenditure 
on medicines in 2007 was 3.2 times higher than in 2002, and the proportion of 
expenditure of medicines on total government health expenditure increased from 5.4% 
to 10.7% over the same period 37.  
 
All Brazilian citizens are eligible for receiving medicines included in the national list of 
essential medicines free of charge through the public health system.  The list covers 
medicines aimed at treating the most prevalent diseases in the country. The public 
health facilities, in general, have a “pharmacy” or “dispensary”. Following consultation 
with a physician, patients can go directly to the pharmacy with a prescription, and 
receive for free the medicines prescribed, provided they are available. If the medicines 
are targeted to treat chronic diseases, the prescription is valid for further allocations 
when the amount provided is finished. Some medicines subject to special control (e.g. 
antipsychotics) are only dispensed at designated public pharmacies. In addition, the 
government provides medicines for treating rare diseases or medicines targeting small 
patient groups, e.g. Crohn’s disease, hepatitis B and C, free of charge. This occurs with 
high cost medicines, when they process follows the criteria established in clinical 
protocols and therapeutic guidelines from the Ministry of Health13. 
 
Charging patients for medicines is strictly prohibited in the public system. The 
government obtains essential medicines through tenders, in which the cheapest 
medicine is selected, and usually the contract lasts for one year. 
 
It has been shown that approximately 50% of the population living in the catchment 
area of a primary health care unit receives medicines free of charge from the public 
sector, 40% purchase their medicines out-of-pocket and 10% obtain them  free from 
other sources (donation or reimbursement from private health insurance)5. 
 
 
i The exchange rate used was US$ 0.43 to each Brazilian Real in 25‐11‐2008. 
(http://www4.bcb.gov.br/pec/conversao/Resultado.asp?idpai=convmoeda) 
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Although in theory the SUS should be able to provide essential medicines free to the 
entire population, medicines are often not available when needed. Studies carried out in 
Brazil have shown that, on average,  40% of the medicines prescribed in primary health 
care were not available when needed29,34. The authors mention serious problems in 
planning and logistics for drug procurement and distribution. These problems may lead 
to interruptions in supply, potential waste due to “expired” medicines, and high 
expenditures for low-priority medicines.   
 
Taking into account that reimbursement for medicine expenses is very rare by Brazilian 
private health insurance plans, expenses on medicines paid for out-of-pocket directly 
impact family budgets and may result in catastrophic expenditures2.  
 
If medicines are not available in public sector facilities, patients purchase them out-of-
pocket in the private market, which may also lead to excessive out-of-pocket spending. 
A study carried out in the Rio Grande do Sul state showed that 12% of the population 
spent more than 40% of their “capacity to pay” (defined as average monthly household 
income adjusted for food expenditure) on health; half of these health expenditures were 
on medicines2.  
 
In order to compensate for these limitations in the availability of free medicines in the 
public sector, the Brazilian government launched the “popular pharmacy” programme in 
2004, financed by the Ministry of Health. The programme sells medicines at low prices 
to the population, particularly those who use private health facilities but who have 
difficulty in buying their medicines in private pharmacies11. There are two types of 
popular pharmacies10: First, there are exclusive popular pharmacies (EPPs) are run by 
the state, city governments, universities or other health-related institutions. In these 
pharmacies, medicines from a list comprising 95 medicines selected on the basis of the 
most commonly prevailing health problems in Brazil or which are expensive for 
individuals to acquire, are sold at cost prices; Second, there are those which are run in 
partnership with private pharmacies using a system of co-payments, created in 2006 as a 
means to expand the popular pharmacy program. In these facilities the government 
covers 90% of the price whereas the patient pays the remaining 10%, but only a list of 
anti-hypertensive, anti-diabetic and contraceptive medicines are sold in this way.  
 
There are crucial differences in the operation of public and private facilities, apart from 
the source of funding of drugs (publicly funded vs. out of pocket). With regards to the 
private sector, medicine dispensing has some unique characteristics. Whereas regulation 
clearly states which medicines can be sold without a prescription9, in reality, consumers 
can purchase medicines without a prescription even in the case of antibiotics, 
antidiabetics, antihypertensives and antiinflammatory agents, among others4. Although 
the law requires that every pharmacy has a pharmacist present at all times, several 
outlets do not follow the rule and employ pharmacists who are rarely present in the 
facility. A study of 595 pharmacies in the South of Brazil, showed that in 12.6% of all 
visits a pharmacist was not present 21.  
 
There are some reasons why people opt to use private health facilities, apart from not 
being able to find a drug in public facilities. For example, better-off individuals who are 
covered by private insurance, in general, opt not to use public facilities because of both 
access problems and the feeling that public facilities are not as good as private ones. In 
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addition, public facilities are located mainly in poor areas distant from the central part 
of the cities.  
 
There are three types of medicines available in the Brazilian market: originator brands, 
generics and similar medicines 6. All generic medicines must be commercialized with 
no brand. Generics are medicines which are interchangeable with the originator brand 
(subject to the standard bioequivalence and bioavailability tests) 7. Similar medicines 
are all the others available on the market. This type of medicine is comparable to 
“branded generics”25 described in the international literature. Branded generics are 
generics whose manufacturers launch them with a particular brand name, which can be 
a ‘fantasy’ or invented name (protected by trademark law), or the name of the 
manufacturer followed by the name of the molecule25. Until recently, similar medicines 
were required to undergo bioequivalence, but not bioavailability tests. The current 
legislation requires them to undergo both tests 8.  
 
Currently, similar medicines are frequently cheaper than “generics” because they do not 
undergo bioequivalence and bioavailability tests with the originator. Although 
legislation stipulates that they should undergo these tests, there is a transition period 
enabling them to be on the market without these tests. This transition period expires at 
the end of 2014.  
 
In summary, lack of availability of medicines in the public sector may lead to (a) out-of-
pocket expenditures, which can unnecessarily compromise families’ budgets; or (b) 
incomplete drug treatments, which may compromise one’s health.   
 
3. Methods 
 
Methodology  
The paper uses the WHO/HAI methodology40 to study price levels, availability and 
affordability of medicines in the Southern Region of Brazil. This methodology enables 
researchers to investigate the (a) prices people pay for key medicinesii; (b) variability of 
prices and availability of medicines in different market segments (public, private and 
other medicine outlets); (c) differences in prices and availability between originator 
brands and generics; and (d) affordability of medicines among “ordinary”iii people40.  
 
The methodology relies on conducting surveys, whose key design elements are: (a) data 
collection takes place in six areas of a selected country or state (in the case of large 
countries, like Brazil); (b) the survey includes pharmacy outlets from both the public 
and private sectors; (c) up to 50 medicines are surveyed; (d) data on prices and 
availability of medicines are obtained by data collectors during visits to the selected 
pharmacy outlets; (e) for each medicine and pharmacy outlet, data are collected on the 
originator brand and the lowest-priced generic.  
 
ii Key medicines are those suitable and used for international comparisons (global and regional list) or 
commonly used therapeutic alternatives to those which are part of the global and regional list. 
iii Ordinary people are defined as the lowest‐paid unskilled government worker. 
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Study area 
The current study has drawn data from the southern region of Brazil (“South”), which is 
one of five geographical regions of the country (South, Southeast, Midwest, Northeast 
and North). The South Region consists of three states (Parana, Santa Catarina and Rio 
Grande do Sul). The sample used in this study was drawn from the state of Rio Grande 
do Sul, which has a total population of 10.5 million, representing 5.7% of the country’ 
total population 24. 
 
Data were collected from six cities within the state: (a) the state capital (Porto Alegre, 
1.4 million inhabitants); (b) two cities in the Southern part of the state (Pelotas and 
Bagé), which are the poorest in the state; (c) one city in the metropolitan area of the 
state capital (São Leopoldo); (d) one city in the richest part of the state (Caxias do Sul); 
and  (e) one city in the central region of the state (Santa Cruz do Sul). The total 
population of these six cities represents one quarter of the state’s total population.  
 
The state of Rio Grande do Sul ranks 6th in the country (out of 26 states) in terms of 
gross domestic product (GDP), with a GDP per capita above the national average of 
R$13,720 (US$5,900) per capita. Poverty and income inequality are below the national 
average 23. GDP varies considerably across the six study cities, with three having a GDP 
per capita below the national and state average (São Leopoldo, Pelotas and Bagé) while 
the remaining three (Porto Alegre, Santa Cruz do Sul e Caxias do Sul) are above these 
averages 23. The proportion of individuals below the poverty threshold was under 30% 
in all cities (below the national average of 36.5%) 24.  
 
Sampling  
The sampling for the survey reflected all ambulatory types of pharmacy outlets. In each 
of the six cities, four public sector facilities with pharmacies were randomly selected 
from a list of all public sector facilities that dispense medicines in each city. The only 
exception was São Leopoldo, where only two health facilities dispensed medicines 
(nph=22). Five private pharmacies per city were also selected and were matched to the 
public sector facilities based on their proximity to them (npp=30). In addition, all EPPs 
(nepp=4) were included in the study. The total sample size was N=56. Pharmacies were 
visited only once, and interviewers requested to see the packaging of all medicines 
surveyed. All pharmacies agreed to take part in the study and a written informed 
consent form was signed prior to data collection.  
 
Data collection and medicines 
Data were collected from the beginning of November 2008 to the end of January 2009. 
Prices and availability of 50 medicines were investigated. Of these, 29 medicines were 
part of the WHO/HAI global and regional core lists, whereas the remainder, the 
supplementary list, were selected from the national (RENAME) and municipal 
(REMUME) lists of essential medicines14. Medicines from the global core list are to be 
included in all medicine price surveys, in order to enable international comparisons. The 
regional core list is study-specific and accounts for regional differences in medicine 
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usage, but still allows for cross-country comparisons within the same broad 
geographical region. The supplementary list of 21 medicines is selected at the country 
level considering local particularities. The REMUME is part of the RENAME list, 
following the local epidemiological profile and is obtained directly from the health 
secretariats of each city. The 50 medicines selected correspond to 12.6% of the 342 
medicines that were part of the national essential list (RENAME) in 2008. The names of 
all medicines included in each list (global, regional and supplementary list) are 
presented in Table 1. 
 
Antidepressants, anti-epileptics and anxiolytics are subject to controlled dispensing and 
are distributed by a restricted number of pharmacies. Due care was exercised to include 
as many of these pharmacies in the sample as possible. 
 
For each selected medicine, data for the following variables were obtained: availability 
at each sampled outlet, patient price for the originator brand, the lowest-priced generic 
and the lowest-priced similar medicine.  
 
Outcome variables 
The study endpoints comprised three measures: availability, medicine prices and 
affordability. Availability was defined as the proportion of pharmacies in which the 
medicines were available at the time of the survey. The mean availability percentage 
was calculated as the average percentage value from all medicines. Prices were 
presented as median price ratios (MPR). The MPR is the ratio of a medicine’s median 
price across outlets divided by the Management Science for Health (MSH) median 
international reference price for the year preceding the survey (2007) 27. Affordability 
was estimated as the number of days that the lowest-paid unskilled government worker 
earning the minimum monthly wage would need to work in order to purchase a 
complete course of treatment in a private pharmacy. The gross minimum monthly wage 
in Brazil in the end of 2008 was R$415 (US$178.50); after excluding 8% for national 
insurance contributions, the adjusted value was R$381.80 (US$165) 15. 
 
Data analysis 
Data entry and analyses were performed using the computerized ExcelR WHO/HAI 
Medicine Pricing Workbook, enhanced for the purpose of including originator brands, 
generics and similar medicines, thus taking into account the peculiarities of the 
Brazilian contextiv.  
 
MPRs in private pharmacies were only calculated if the medicine was available on, at 
least, four facilities. In the case of popular pharmacies, due to the small sample size, 
calculations of MPR were performed if the medicine was available in at least one 
facility. Median price differences across the three types of medicines included only 
medicines for which the pair was found in at least one facility. 
 
 
iv All collected data (price and availability) were entered in the workbook, consolidated and summarized. 
Data were entered twice in order to avoid entry errors. Based on the unique feature of the Brazilian 
medicines market, comprising originators, generics and similar medicines, three workbooks were 
analyzed: originator brands vs. generics, originator brands vs. similars, and generics vs. similars. 
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In order to estimate the mean availability of medicines in the EPPs, only 36 medicines 
were included in this part of the analysis, as the remaining 14 were not commercially 
available in this type of facility. To avoid underestimation of availability of generic 
medicines, all cases in which generics were not available in the Brazilian market were 
excluded from the calculations of availability.  
 
4. Results 
 
Table 1 describes all medicines studied in terms of pharmacological groups, their 
presence or not in the Brazilian list of essential medicines (RENAME) and availability 
of the three types of medicines in the public and private sectors. Out of the 50 medicines 
studied, 43 are part of RENAME. The following medicines, which come either from the 
global or from the regional list, are neither part of RENAME nor REMUME: 
atorvastatin 10mg tab, clotrimazole 10mg/g cr, ibuprofen 400mg cap and sinvastatin 
20mg tab.  
 
Table 2 shows the mean proportion of availability in the public sector. As expected, no 
originator brands were found in public sector facilities. Mean availability of similar 
medicines was 2-7 times greater than that of generics; this difference was larger in the 
poorest cities (São Leopoldo, Pelotas and Bagé) compared to the wealthier ones. 
Availability, independently of the type of medicine (generic or similar), was 78.3% in 
Porto Alegre, 71.5% in Santa Cruz,  76.4% in Caxias do Sul,  80.3% in São Leopoldo, 
68.8% in Pelotas and 81.7% in Bagé.  
 
Mean availability of lowest-priced generics was lowest in popular pharmacies of the 
two poorest cities (São Leopoldo e Bagé) and availability of lowest-priced similar 
medicines was lower in the two wealthier ones (Porto Alegre e Caxias do Sul) (Table 
3). No originator brands were found in popular pharmacies. Mean availability, 
independently of the type of medicine (generic or similar), was greater than 90% in all 
cities: 91.6% in Porto Alegre, 91.6% in Caxias do Sul,  97.2% in São Leopoldo and 
97.3% in Bagé. In relation to prices, the values were very similar for the lowest-priced 
similar medicines, but ranged from 2.6 to 4.1 MPR for the lowest-priced generics. 
 
Table 4 presents data on the availability of medicines and prices in the private sector. 
Mean availability of originator brands ranged from 48 to 91%; equivalent figures were 
63 to 88% for lowest-priced generics and 39 to 55% for lowest-priced similar 
medicines. The availability of originator brands was higher in the two poorest cities 
(Pelotas and Bagé). Overall, mean availability was 65%, 74% and 48% for originator 
brands, generics and similar medicines, respectively. In terms of MPR, values ranged 
from 8.6 for lowest-priced similar medicines to 18.7 for originator brands; MPR was 
11.3 for lowest-priced generics. 
 
Taking into account all cities together, the price of both generics and similar medicines 
is roughly half the price of originator brands (Figure 1). The greatest difference between 
similar medicines and originator brands was found in Bagé (similar medicines were 
62% cheaper than originator brands) whereas the smallest difference was found in São 
Leopoldo (generics were 40% cheaper than originator brands).  
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The price difference recorded between originator brand and generics or similar 
medicines have significant implications for affordability (Figure 2).  A seven-day 
treatment with originator brand ciprofloxacin 500mg would cost 13.7 days of salary; the 
equivalent figures were 2.2 and 1.9 days for similar and generic medicines. For a seven-
day treatment with amoxicillin 500mg, the values are 3.4 (originator brand) and 1.1 and 
1.2 days (similar and generic medicines). For a 30-day diabetes treatment with 
glibenclamide 5mg, the differences were very small (values around 1.0 day for similar 
and generic medicines and 1.5 for originator brand). A 30-day ulcer treatment with 
ranitidine 150mg would cost 9.2 (originator brand) and 3.3 and 3.0 days (generics and 
similar medicines respectively). The originator medicine for a 30-day treatment for 
asthma (salbutamol inhaler, 200 doses) would cost 2.1 (originator brand) and 1.6 days 
(similar medicine). No generics are available for salbutamol inhaler in the Brazilian 
market.   
 
5. Discussion 
 
Our results suggest, first, that prices of generics and similar medicines are, on average, 
half those of originator brands. The MPR for all medicines (brands, generics and 
similars) was found in all cases to be significantly greater than one, indicating that 
prices in Brazil are higher than international reference prices. Public sector availability 
of generics or similar medicines is lower than expected and, consequently, patients 
resort more often to purchasing medicines in private pharmacies, where availability is 
higher, but prices are high and patients have to pay fully out-of-pocket, thus impacting 
affordability. 
 
In private sector pharmacies, generics were the most likely medicines to be available, 
followed by originator brands and similar medicines. Because reimbursement of 
medicines is very rare in Brazil, private pharmacies typically try to offer all types of 
medicines, so that consumers from all social classes are able to obtain their medicines. 
In the recent past, generics accounted for only a small proportion of the medicines 
market in Brazil4, because people were more likely to buy either the cheapest medicine 
(usually a similar) or the originator brand based on the belief that the latter were of 
better quality than generics or similar medicines. In recent years,  the market share of 
generics has increased significantly both in absolute terms and in comparison with 
originator brands and similar medicines32.   
 
Mean availability of generics in the private sector was 73.8%, a figure comparable to 
those observed in the Americas, Eastern Mediterranean, Europe and Southeast Asia and 
higher than those in Africa or Western Pacific, whereas mean availability of originator 
brands (64.8%) was similar to that found in upper middle income countries (61.8%)17. 
Private sector MPRs were lowest for the similar medicines, a finding consistent with 
previous research28.  
 
Availability of medicines in the public sector was at or above 69% in all cities, and was 
slightly lower than availability investigated in another study 30. Placing our availability 
findings in an international context we find that availability in Brazil is lower than that 
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of Sudan (82%)18, but higher than that in Malaysia (5-40%, depending on the 
medicine)1, India (0-30%, depending on the region of the country) 26 and Chinese rural 
areas (38.9%)41.  
 
Still, our findings on availability are poor considering that all Brazilian citizens should 
have access to all essential medicines free of charge, a right which is constitutionally 
protected12. The lack of several medicines in the public sector forces patients to 
purchase their medicines out-of-pocket in private sector outlets and may lead to 
catastrophic health expenses 2 and/or undertreatment 34.  
 
Our affordability findings varied by therapeutic class and type of medicine and are 
attributable to poor availability in the public sector. Although the lowest-paid unskilled 
government worker salary was used as a measure of affordability it is likely that a 
significant part of the population earns less17. In Brazil, 32.8% of the population live 
below the poverty line of US$1 per day24. For these people, any out-of-pocket expense 
related to medicines could be catastrophic.  
 
Availability of generic medicines in the public sector was 9-23% in all cities studied, 
whilst availability of similar medicines was 56 – 70%. These are comparable to those in 
other regions of the country, where similar medicines are more widely available 
(86.4%) than generics (25%) 28.  
 
The different levels of availability observed in each city may partly reflect two trends; 
first, decentralization of the Brazilian public health system, whereby municipalities fund 
a proportion of medicines directly out of their budgets; and second, differences in 
medicines distribution, where supply of public sector facilities is often problematic 
(inadequate quantities, problems with frequency and time of distribution, and inefficient 
stock control, among others)20,30.  
 
The availability of medicines which are part of the list of the popular pharmacies was 
high (>90% in all cities). Similar results have been described in other regions of the 
country 19. As in public sector facilities, similar medicines are also more frequently 
available than generics in popular pharmacies. Retail prices in popular pharmacies are 
standardized, and, therefore, differences observed across cities reflect the fact that 
different medicines were available in each facility, thus resulting in a different mean 
value. Popular pharmacies, in theory, may represent an important additional source of 
access to medicines for the population, given that prices are much lower than those 
observed in private pharmacies. Yet, the number of popular pharmacies is low and the 
list of medicines provided is limited. The fact that a high proportion of the users of the 
programme are also SUS users – 39.2% according to a recent study33 - suggests that the 
lack of medicines in the public system is a reality, and patients often need to use popular 
pharmacies in order to obtain essential medicines, which should be supplied  free by the 
government.  
 
The highest median price difference between originator brand and the lowest-priced 
generic was 60%. Between 2000 to 2004, when generic medicines were launched in 
Brazil, the mean price difference between generics and originator brand products was 
40% but this tended to increase over time38. Both types of medicines presented absolute 
13 
 
increases in their prices, but the increase in the price of the originator brand was 
relatively higher than that of the generic equivalent(s)38.  
 
An analysis of different types of medicines suggests low availability of antidepressants, 
anti-epileptics and anxiolytics in the public system. This could be explained by the way 
these medicines are dispensed. Because their dispensing is tightly regulated, they are 
available in specific facilities in some cities. If we consider only the facilities which are 
able to distribute these medicines, availability ranges from 75 to 100%. 
The analysis is not without limitations. Caution should be exercised when extrapolating 
our data to the national level because there may be regional differences in public and 
private sector availability of medicines across the different regions of the country. Such 
differences may reflect different priorities in health care given the different profiles of 
morbidity outside the study region. Still, our results compare well with other studies 
conducted in Brazil. There may be differences in prices between this region and other 
regions in the country, partly because of differences in sales taxes, but these are 
marginal and are unlikely to affect our comparisons with other national-level evidence. 
Because the proportion of informal work varies considerably across regions of the 
country, care should be exercised when extrapolating our affordability findings to the 
national level. Finally, there are inherent limitations relating to the WHO/HAI 
methodology but these have been discussed elsewhere 17.  
 
6. Conclusions and pharmaceutical policy implications 
 
High prices, poor availability in public sector facilities and low affordability suggest a 
number of policy implications for the Brazilian government. First, it needs to maintain 
its commitment of providing a list of essential medicines free of charge at public 
facilities, aiming to fulfill the target of 100% availability for this list of medicines. 
Second, the participation of generic products in the market needs to be increased and 
their prices reduced further, through better tendering processes, so that generics become 
cheaper than similar products. Although generics and similar medicines are alternatives 
to originator brands, they are also 8.6 - 11.3 more expensive than international reference 
prices. Therefore, an overall reduction in medicine prices should be a key priority. In 
order to achieve this, reductions in taxes and duties on medicines, and margin 
regulations in the supply chain could be considered. Policy measures used in developed 
country settings and evidence on their performance could be used in the Brazilian 
context25. Third, the routines of acquisition, stock and distribution of medicines in the 
public sector need to be re-evaluated, ensuring adequate and timely distribution of 
essential medicines. The use of information and communication technologies should be 
prioritized. Fourth, if the government continues to be unable to provide for free all 
essential medicines needed by the population, it is necessary to expand the popular 
pharmacy programme, by increasing the number of facilities and the number of 
medicines available. Alongside that, the quantity and quality of information available to 
patients about prices should also improve. Finally, the private market requires tighter 
regulation, so that only OTC medicines are dispensed without a prescription.  
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Table 1.  List of the medicines investigated (N=50) according to therapeutic classes, methodology list belonged to, presence in the Brazilian list of essential medicines 
(RENAME) and in the Popular Pharmacy Programme, and mean % availability in the public and private sector of the three types of medicines (originator brand, similar 
medicines and generics). Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.   
 
Mean % availability 
Public1                 Private 
 
Therapeutic class
 
  
 
Medicine 
 
 
Methodology list 
  
 
RENAME 
2008 
 
Popular 
pharmacy 
N2 Generic Similar N3 Generic N4 Similar Originator 
brand 
Analgesic Paracetamol 500 mg tab 
 
Supplementary Yes Yes 5 77.8 11.1 12 46.7 14 60.0 60.0 
Anthelmintic 
 
Mebendazole 20 mg/ml susp Supplementary No Yes 6 9.1 86.4 16 83.3 30 50.0 83.3 
Amitriptyline 25 mg tab5 Global Yes Yes 6 4.5 27.3 10 86.7 6 53.3 70.0 Antidepressant 
Fluoxetine 20 mg cap5 
 
Regional Yes No 1 0 25.0 11 93.3 11 70.0 26.7 
Glibenclamide 5 mg tab Global Yes Yes 6 0 100.0 7 73.3 15 70.0 83.3 Antidiabetis 
Metformin 850 mg tab 
 
Regional Yes Yes 6 22.7 77.3 17 90.0 14 56.7 90.0 
Carbamazepine 200 mg tab5 Supplementary Yes Yes 6 4.5 27.3 11 86.7 6 13.3 66.7 
Clonazepam 2mg tab5 Regional Yes No 2 0 25.0 5 43.3 5 16.7 93.3 
Antiepileptic 
Phenytoin 100 mg tab5 
 
Regional Yes Yes 6 22.7 9.1 3 60.0 3 3.3 93.3 
Miconazole 20 mg/g cr Supplementary Yes No 5 56.6 16.7 9 83.3 10 16.7 33.3 Antifungic 
Nystatin 100,000 UI/ml susp 
 
Supplementary Yes Yes 4 57.5 0 9 90.0 16 30.0 63.3 
Amlodipine 5 mg tab Regional Yes No 0 - - 16 76.7 14 46.7 36.7 
Atenolol 50 mg tab Global Yes No 0 - - 17 90.0 13 76.7 76.7 
Captopril 25 mg tab Global Yes Yes 6 18.2 81.8 16 86.7 35 76.7 36.7 
Enalapril 10 mg tab Regional Yes Yes 3 0 66.6 15 86.7 29 93.3 60.0 
Methyldopa 250 mg tab Supplementary Yes Yes 5 0 83.3 4 70.0 16 40.0 70.0 
Nifedipine 10mg tab Supplementary Yes No 5 0 59.0 0 0 5 36.7 66.7 
Antihypertensive 
 
Propranolol 40 mg tab Supplementary Yes Yes 6 0 100.0 8 80.0 20 63.3 73.3 
 Verapamil 80 mg tab 
 
Supplementary Yes Yes 4 12.5 71.3 8 90.0 6 26.7 70.0 
Amoxicillin 500 mg tab Global Yes Yes 6 31.8 68.2 23 100.0 28 60.0 56.7 
Amoxicillin 50 mg/ml susp Regional Yes Yes 6 0 90.9 14 93.3 12 53.3 63.3 
Azithromycin 500 mg tab Regional Yes Yes 1 0 25.0 10 73.3 19 86.7 26.7 
Benzylpenicillin-benzathin 1200000 U.I./vial inj  Supplementary Yes Yes 6 0 77.3 0 0 2 0 90.0 
Antiinfective 
 
Cefalexin 500 mg tab Supplementary Yes Yes 5 33.3 22.2 13 86.7 16 16.7 60.0 
...continuation of table 1. 
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Mean % availability 
Public1                 Private 
 
 Therapeutic class 
 
 
Medicine 
 
 
Methodology 
list 
  
 
RENAME 
2008 
 
Popular 
pharmacy
N2 Generic Similar  N3 Generic N4 Similar Originator brand 
Cefalexina 50 mg/ml susp Supplementary Yes Yes 5 22.2 44.4  7 83.3 11 30.0 40.0 
Ceftriaxone 1g/vial inj    Global Yes No 0 - -  9 66.7 3 23.3 20.0 
Ciprofloxacin 500mg tab Global Yes Yes 1 0 25.0  15 80.0 21 66.7 33.3 
Co-trimoxazole 80+400mg tab Supplementary Yes Yes 6 9.1 77.3  1 26.7 28 73.3 86.7 
Co-trimoxazole 8+40mg/ml susp Global Yes Yes 6 0 72.7  3 66.7 28 53.3 93.3 
Clotrimazole 10 mg/g cr Regional No No 0 - -  12 66.7 18 43.3 96.7 
Doxycycline 100 mg tab Supplementary Yes Yes 3 0 91.6  1 50.0 7 36.7 53.3 
Erythromycin 500 mg tab Supplementary Yes Yes 6 0 86.4  0 0 10 53.3 63.3 
Erythromycin 50 mg/ml susp Supplementary Yes Yes 6 0 77.3  0 0 7 30.0 53.3 
Metronidazole 250 mg tab Supplementary Yes Yes 5 38.9 27.8  3 63.3 16 20.0 73.3 
Antiinfective 
Metronidazole 400 mg tab 
 
Regional Yes No 2 37.5 25.0  2 73.3 4 33.3 86.7 
Bec lometasone 250 mcg/dose inhaler Regional Yes No 3 0 0  0 0 1 10.0 46.7 
Dic lofenac sodium 50 mg tab Global No No 1 0 75.0  9 76.7 36 93.3 90.0 
Ibuprofen 400 mg cap Regional No No 0 - -  0 0 0 0 0 
Antiinflammatory 
 
Prednisone 5 mg tab 
 
Supplementary Yes Yes 5 11.1 88.9  10 90.0 10 60.0 93.3 
Antithrombotic agent Acetylsalicylic acid 100mg tab  
 
Supplementary Yes Yes 6 18.2 86.4  5 76.7 8 86.7 86.7 
Anxiolytic Diazepam 5 mg tab5 
 
Global Yes Yes 2 0 25.0  3 70.0 7 46.7 70.0 
Cardiac therapy Digoxin 0,25 mg tab 
 
Supplementary Yes Yes 6 40.9 63.6  3 73.3 9 46.7 73.3 
Furosemide 40 mg tab Regional Yes Yes 6 0 100.0  6 70.0 17 76.7 93.3 Diuretic 
Hydrochlorothiazide 25 mg tab 
 
Regional Yes Yes 6 9.1 95.5  5 56.7 5 83.3 90.0 
Omeprazole 20 mg cap Global Yes Yes 4 0 82.5  10 86.7 37 90.0 46.7 Drug for acid related disorder 
Ranitidine 150 mg tab 
 
Regional Yes Yes 1 0 100.0  12 76.7 27 43.3 43.3 
Drug for obstructive airway 
disease 
Salbutamol 100mcg/dose inhaler Global Yes No 2 0 52.5  0 0 3 63.3 86.7 
 Salbutamol xar 2mg/5ml syrup Supplementary No Yes 6 45.5 31.8  11 80.0 21 10.0 73.3 
              
Lipide modifying agent Atorvastatin 10 mg tab Regional No     No 0 - -  0 0 1   20.0 53.3 
 Simvastatin 20 mg tab Global No Yes 0 - -  7 70.0 15 93.3 33.3 
 1  No originator brand was located in the public sector           2 Out of the six cities studied, in how many the medicine was part of the list of essential medicines  3  Number of generics available in the market     
4 Number of similar medicines available in the market      5 Medicines subject to especial control. In some cities, they are distributed in specific pharmacies only   
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 Table 2. Mean availability (%) of medicines1 in the public sector (n=22 facilities). Sample of 
six cities from the Rio Grande do Sul state, Brazil, 2008-9.   
Lowest-priced generic  
Lowest-priced 
similar City N 
Mean %2 SD %3  Mean % SD % 
Porto Alegre  30 23.3 41.9 55.8 41.9 
Santa Cruz do Sul  38 14.5 31.6  59.9 39.7 
Caxias do Sul 35 17.1 32.5 60.7 39.4 
São Leopoldo  33 13.6 31.3 69.7 43.2 
Pelotas  32 8.9 21.0 61.7 39.6 
Bagé  26 11.5 27.6 70.2 38.1 
1Only medicines included in the list of essential medicines within each city were included in this analysis 
2Mean avalability %  3Standard deviation % 
      
 
Table 3. Availability and price of the 36 medicines dispensed by the Popular Pharmacy (n=4 
facilities). Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.   
 Lowest-priced generic  Lowest-priced similar 
n1 Price Availability n Price Availability City 
  MPR2 (Min - Max) Mean % (SD)   MPR (Min - Max) Mean % (SD) 
Porto Alegre 8 3.63 (1.30 - 11.41) 22.2 (42.2) 25 2.61 (0.33 - 15.17) 69.4 (46.7) 
Caxias do Sul 8 2.88 (1.30 - 11.41) 22.2 (42.2) 25 2.61 (0.33 - 15.17) 69.4 (46.7) 
São Leopoldo 7 2.64 (1.30 - 11.41) 19.4 (40.1) 28 2.86 (0.33 - 15.17) 77.8 (42.2) 
Bagé 6 4.12 (1.30 - 11.41) 16.7 (37.8) 29 2.61 (0.33 - 15.17) 80.6 (40.1) 
Total 10 2.88 (1.30 - 11.41) 20.1 (35.8) 31 2.64 (0.33 - 15.17) 74.3 (38.0) 
1 Number of medicines included in the analysis of the MPR 
2 MPR= Median price ratios (= median prices / IRP)   IRP = International reference prices (MSH, 2007) 
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Table 4. Availability of medicines and prices in the private sector (n=30 pharmacies). Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.   
Originator brand Lowest-priced generic Lowest-priced similar 
 
 
City 
N1 MPR2 (min - max) Availability (SD)3 n MPR (min - max) Availability (SD) n MPR (min - max) Availability (SD) 
Porto Alegre  23 17.06 (2.70 - 94.58) 57.6% (37.6%) 21 9.97 (0.93 - 34.36) 63.3% (28.6%) 18 15.61 (3.17 - 37.87) 54.4% (33.1%) 
Santa Cruz do Sul  18 25.99 (2.60 - 87.57) 57.6% (30.1%) 11 9.88 (0.85 - 37.76) 68.8% (22.8%) 23 18.34 (1.88 - 32.49) 39.2% (32.8%) 
Caxias do Sul 17 30.63 (2.70 - 94.68) 58.0% (23.3%) 25 11.33 (0.93 - 48.92)  71.2% (25.6%) 14 12.40 (1.86 - 37.48) 47.2% (30.4%) 
São Leopoldo  15 29.40 (4.90 - 66.45) 48.4% (28.3%) 17 8.42 (0.85 - 33.93) 65.6% (26.3%) 17 8.18 (2.75 - 38.82) 52.0% (31.6%) 
Pelotas  35 19.08 (2.70 - 107.47) 75.6% (26.9%) 34 9.76 (0.87 - 48.95) 85.6% (25.3%) 10 9.36 (2.94 - 22.37) 41.2%  (27.5%)  
Bagé  46 16.73 (1.32 - 162.53) 91.0% (15.7%) 39 9.55 (0.36 - 49.82) 88.4% (20.6%) 20 8.81 (1.26 - 36.45) 54.8% (33.3%) 
All  49 18.66 (1.36 -168.41) 64.8% (22.8%) 42 11.32 (0.84 - 54.94) 73.8% (18.8%) 45 8.60 (1.11 - 38.84) 48.1% (26.8%) 
1 N = Total number of medicines included in the analysis. To calculate the MPR, we only included medicines which were available on at least four facilities.  
2 MPR= Median price ratios (= median prices / IRP)   IRP = International reference prices (MSH, 2007) 
3 Mean avalability % (standard deviation) 
‐70 ‐60 ‐50 ‐40 ‐30 ‐20 ‐10 0
Porto Alegre
Santa Cruz do Sul
Caxias do Sul
São Leopoldo
Pelotas
Bagé
Overall
%
Similar Generic
Figure 1. Median price difference (%) of generic and similar medicines in relation to originator 
brand medicines in the private sector for matched pairs of medicines available on at least one 
facility.  Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.   
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Figure 2. Affordability (%) of generic, originator brand and similar medicines using a list of 
selected medicines. Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.   
 
* Generic medicines of the salbutamol 0.1 mg/dose inhaler were not available at the time of data collection. 
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